Letermovir for the Management of Cytomegalovirus-associated Uveitis

ABSTRACT

Purpose: To investigate the use of letermovir 480 mg daily for the treatment of cytomegalovirus (CMV)-associated uveitis (AU).

Methods: Retrospective case series of CMV-AU patients on letermovir.

Results: Six eyes of five patients (mean age 54 years) were included. Mean follow-up time was 10 months. Four patients had CMV anterior uveitis and one patient had bilateral CMV retinitis. All were treated initially with valganciclovir 900 mg twice daily. Transition to letermovir was due to cytopenias (n = 3), transaminitis (n = 1), and persistent inflammation on valganciclovir (n = 1). At the initiation of letermovir, mean visual acuity (VA) was 0.35 logMAR and IOP was 14 mmHg. One of the six eyes had a recurrence of anterior uveitis due to self-discontinuation of letermovir. No adverse events were observed. At last follow-up, no patients had active inflammation. Mean VA was 0.08 logMAR and IOP was 9 mmHg.

Conclusion: Letermovir may be an alternative treatment for CMV-AU in patients with persistent inflammation or side effects on valganciclovir.

KEYWORDS:

• Letermovir
• cytomegalovirus
• uveitis
• valganiciclovir
• retinitis

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Financial disclosures

JGS: Santen Inc. (Consultant, Grant Support)

Additional information

Funding

Research reported in this manuscript was supported by Building Interdisciplinary Careers in Women’s Health of the National Institutes of Health K12HD085850 (JGS) and the Research to Prevent Blindness Career Development Award (TD).